▶ 調査レポート

非定型抗精神病薬の世界市場レポート2020

• 英文タイトル:Covid-19 Impact on Global Atypical Antipsychotic Drugs Sales Market Report 2020

QYResearchが調査・発行した産業分析レポートです。非定型抗精神病薬の世界市場レポート2020 / Covid-19 Impact on Global Atypical Antipsychotic Drugs Sales Market Report 2020 / 20QY06-08230資料のイメージです。• レポートコード:20QY06-08230
• 出版社/出版日:QYResearch / 2020年6月3日
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、142ページ
• 納品方法:Eメール(受注後2~3営業日)
• 産業分類:医薬品・医療
• 販売価格(消費税別)
  Single User¥592,000 (USD4,000)▷ お問い合わせ
  Multi User¥888,000 (USD6,000)▷ お問い合わせ
  Enterprise License¥1,184,000 (USD8,000)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
QYResearch社の当調査資料では、非定型抗精神病薬のグローバル市場について種類別(リスペリドン、オランザピン、ケチアピン、ジプラシドン、その他)、用途別(双極性I型障害、統合失調症、統合失調感情障害、大うつ病性障害(MDD))、地域別(北米、ヨーロッパ、中国、日本、東南アジア、インド)に区分して調査し、纏めました。2015年~2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。

・非定型抗精神病薬市場の概要
・世界の主要地域別非定型抗精神病薬市場規模2015-2026
・主要プレイヤーの競争状況・市場シェア
・世界の非定型抗精神病薬市場規模2015-2026:種類別(リスペリドン、オランザピン、ケチアピン、ジプラシドン、その他)
・世界の非定型抗精神病薬市場規模2015-2026:用途別(双極性I型障害、統合失調症、統合失調感情障害、大うつ病性障害(MDD))
・非定型抗精神病薬の北米市場規模2015-2020
・非定型抗精神病薬のヨーロッパ市場規模2015-2020
・非定型抗精神病薬の中国市場規模2015-2020
・非定型抗精神病薬の日本市場規模2015-2020
・非定型抗精神病薬の東南アジア市場規模2015-2020
・非定型抗精神病薬のインド市場規模2015-2020
・主要プレイヤーの企業情報:事業概要・売上・企業動向
(Novartis AG、Cardinal Health、Johnson and Johnson、Allergan、Sanis Health、Pfizer、GlaxoSmithKline、Bristol-Myers Squibb Company、Sun Pharmaceutical Industries、Eil Lilly and Company、AstraZeneca、Sumitomo Dainippon Pharma、Qilu Pharmaceutical)
・非定型抗精神病薬の製造コスト分析
・販売チャネル、流通業者、顧客
・非定型抗精神病薬の市場動向・機会・課題
・調査の結論

A recently published report by QY Research titled Global Atypical Antipsychotic Drugs Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate data in a statistical manner. It examines the historic accomplishments and recent opportunities present in the global Atypical Antipsychotic Drugs market. QY Research report focuses on the consumption, geography, by type, by application, and the competitive landscape. The 4000 version of the report mainly splits the data for each region to analyze the leading companies, applications, and product types.
QY Research aims to provide a complete knowledgeable report so that the readers will benefit from it. The report is properly examined and compiled by industry experts and will shed light on the key information that requires from the clients.
Report Overview:
Atypical antipsychotic drugs are a type of antipsychotic drugs used in treatment of psychosis. They do not cure psychosis but help in controlling symptoms such as hallucinations, and delusions, among others.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Atypical Antipsychotic Drugs market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Atypical Antipsychotic Drugs industry.
Based on our recent survey, we have several different scenarios about the Atypical Antipsychotic Drugs YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Atypical Antipsychotic Drugs will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
QY Research report provides an overview and scope of the global Atypical Antipsychotic Drugs market, stating its drivers, trends, opportunities, and restraints. The report also comprises all key details of the global Atypical Antipsychotic Drugs market such as market strategies, sales volumes, and consumption. The report also covers the names of all distribution channels such as manufacturers, suppliers, wholesalers, distributors, consumers, and dealers.
QY Research also presents the statistical data in the form of infographics, tables, and charts to predict the trends and developments of the global Atypical Antipsychotic Drugs market over the forecast period. The research analysts have also used a framework such as key industry experts interview, research papers, refer journals, survey reports, and face-to-face interviews with expert professionals to know the detailed outlook of the global Atypical Antipsychotic Drugs market. The report also includes nautical information, where it shows Atypical Antipsychotic Drugs market product volume, utilization value, and production processes.
The research report also consists of a competitive landscape that describes the top players that are functioning in the global Atypical Antipsychotic Drugs market. This report also describes the key developments and trends, mergers and acquisitions strategies, and new product innovation that will show an enormous benefit to the companies that are competing in the global Atypical Antipsychotic Drugs market.
Geographical Analysis:
Based on region, the global Atypical Antipsychotic Drugs market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players:
The major players that are operating in the global Atypical Antipsychotic Drugs market are
Novartis AG
Cardinal Health
Johnson and Johnson
Allergan
Sanis Health
Pfizer
GlaxoSmithKline
Bristol-Myers Squibb Company
Sun Pharmaceutical Industries
Eil Lilly and Company
AstraZeneca
Sumitomo Dainippon Pharma
Qilu Pharmaceutical
Segment by Type
Risperidone
Olanzapine
Quetiapine
Ziprasidone
Others
Segment by Application
Bipolar I Disorder
Schizophrenia
Schizoaffective Disorder
Major Depressive Disorder (MDD)
Competitive Landscape:
Factors such as cost analysis, marketing strategy, factor analysis, distributors, sourcing strategy, and industrial chain are all the parts of the global Atypical Antipsychotic Drugs market. The report also includes the analysis of the return on investment (ROI) feasibility with the estimated SWOT analysis.
The report covers the following objectives:
• Proliferation and maturation of trade in the global Atypical Antipsychotic Drugs market.
• The market share of the global Atypical Antipsychotic Drugs market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
• Current and future market trends that are influencing the growth opportunities and growth rate of the global Atypical Antipsychotic Drugs market.
• Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global Atypical Antipsychotic Drugs market.

レポート目次

1 Atypical Antipsychotic Drugs Market Overview
1.1 Atypical Antipsychotic Drugs Product Scope
1.2 Atypical Antipsychotic Drugs Segment by Type
1.2.1 Global Atypical Antipsychotic Drugs Sales by Type (2020-2026)
1.2.2 Risperidone
1.2.3 Olanzapine
1.2.4 Quetiapine
1.2.5 Ziprasidone
1.2.6 Others
1.3 Atypical Antipsychotic Drugs Segment by Application
1.3.1 Global Atypical Antipsychotic Drugs Sales Comparison by Application (2020-2026)
1.3.2 Bipolar I Disorder
1.3.3 Schizophrenia
1.3.4 Schizoaffective Disorder
1.3.5 Major Depressive Disorder (MDD)
1.4 Atypical Antipsychotic Drugs Market Estimates and Forecasts (2015-2026)
1.4.1 Global Atypical Antipsychotic Drugs Sales Growth Rate (2015-2026)
1.4.2 Global Atypical Antipsychotic Drugs Revenue and Growth Rate (2015-2026)
1.4.3 Global Atypical Antipsychotic Drugs Price Trends (2015-2026)
1.5 Coronavirus Disease 2019 (Covid-19): Atypical Antipsychotic Drugs Industry Impact
1.5.1 How the Covid-19 is Affecting the Atypical Antipsychotic Drugs Industry
1.5.1.1 Atypical Antipsychotic Drugs Business Impact Assessment – Covid-19
1.5.1.2 Supply Chain Challenges
1.5.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.5.2 Market Trends and Atypical Antipsychotic Drugs Potential Opportunities in the COVID-19 Landscape
1.5.3 Measures / Proposal against Covid-19
1.5.3.1 Government Measures to Combat Covid-19 Impact
1.5.3.2 Proposal for Atypical Antipsychotic Drugs Players to Combat Covid-19 Impact

2 Atypical Antipsychotic Drugs Estimate and Forecast by Region
2.1 Global Atypical Antipsychotic Drugs Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Atypical Antipsychotic Drugs Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Atypical Antipsychotic Drugs Sales Market Share by Region (2015-2020)
2.2.2 Global Atypical Antipsychotic Drugs Revenue Market Share by Region (2015-2020)
2.3 Global Atypical Antipsychotic Drugs Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Atypical Antipsychotic Drugs Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Atypical Antipsychotic Drugs Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Atypical Antipsychotic Drugs Estimates and Projections (2015-2026)
2.4.2 Europe Atypical Antipsychotic Drugs Estimates and Projections (2015-2026)
2.4.3 China Atypical Antipsychotic Drugs Estimates and Projections (2015-2026)
2.4.4 Japan Atypical Antipsychotic Drugs Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Atypical Antipsychotic Drugs Estimates and Projections (2015-2026)
2.4.6 India Atypical Antipsychotic Drugs Estimates and Projections (2015-2026)
3 Global Atypical Antipsychotic Drugs Competition Landscape by Players
3.1 Global Top Atypical Antipsychotic Drugs Players by Sales (2015-2020)
3.2 Global Top Atypical Antipsychotic Drugs Players by Revenue (2015-2020)
3.3 Global Atypical Antipsychotic Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Atypical Antipsychotic Drugs as of 2019)
3.4 Global Atypical Antipsychotic Drugs Average Price by Company (2015-2020)
3.5 Manufacturers Atypical Antipsychotic Drugs Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Atypical Antipsychotic Drugs Players (Opinion Leaders)
4 Global Atypical Antipsychotic Drugs Market Size by Type
4.1 Global Atypical Antipsychotic Drugs Historic Market Review by Type (2015-2020)
4.1.1 Global Atypical Antipsychotic Drugs Sales Market Share by Type (2015-2020)
4.1.2 Global Atypical Antipsychotic Drugs Revenue Market Share by Type (2015-2020)
4.1.3 Global Atypical Antipsychotic Drugs Price by Type (2014-2020)
4.2 Global Atypical Antipsychotic Drugs Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Atypical Antipsychotic Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Atypical Antipsychotic Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Global Atypical Antipsychotic Drugs Price Forecast by Type (2021-2026)
5 Global Atypical Antipsychotic Drugs Market Size by Application
5.1 Global Atypical Antipsychotic Drugs Historic Market Review by Application (2015-2020)
5.1.1 Global Atypical Antipsychotic Drugs Sales Market Share by Application (2015-2020)
5.1.2 Global Atypical Antipsychotic Drugs Revenue Market Share by Application (2015-2020)
5.1.3 Global Atypical Antipsychotic Drugs Price by Application (2015-2020)
5.2 Global Atypical Antipsychotic Drugs Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Atypical Antipsychotic Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Atypical Antipsychotic Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Atypical Antipsychotic Drugs Price Forecast by Application (2021-2026)

3 North America Atypical Antipsychotic Drugs Market Facts & Figures
3.2 North America Atypical Antipsychotic Drugs Sales Market Share by Company (2015-2020)
3.3 North America Atypical Antipsychotic Drugs Sales Market Share by Type (2015-2020)
3.4 North America Atypical Antipsychotic Drugs Sales Market Share by Application (2015-2020)

4 Europe Atypical Antipsychotic Drugs Market Facts & Figures
4.2 Europe Atypical Antipsychotic Drugs Sales Market Share by Company (2015-2020)
4.3 Europe Atypical Antipsychotic Drugs Sales Market Share by Type (2015-2020)
4.4 Europe Atypical Antipsychotic Drugs Sales Market Share by Application (2015-2020)

5 China Atypical Antipsychotic Drugs Market Facts & Figures
5.2 China Atypical Antipsychotic Drugs Sales Market Share by Company (2015-2020)
5.3 China Atypical Antipsychotic Drugs Sales Market Share by Type (2015-2020)
5.4 China Atypical Antipsychotic Drugs Sales Market Share by Application (2015-2020)

6 Japan Atypical Antipsychotic Drugs Market Facts & Figures
6.2 Japan Atypical Antipsychotic Drugs Sales Market Share by Company (2015-2020)
6.3 Japan Atypical Antipsychotic Drugs Sales Market Share by Type (2015-2020)
6.4 Japan Atypical Antipsychotic Drugs Sales Market Share by Application (2015-2020)

7 Southeast Asia Atypical Antipsychotic Drugs Market Facts & Figures
7.2 Southeast Asia Atypical Antipsychotic Drugs Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Atypical Antipsychotic Drugs Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Atypical Antipsychotic Drugs Sales Market Share by Application (2015-2020)

8 India Atypical Antipsychotic Drugs Market Facts & Figures
8.2 India Atypical Antipsychotic Drugs Sales Market Share by Company (2015-2020)
8.3 India Atypical Antipsychotic Drugs Sales Market Share by Type (2015-2020)
8.4 India Atypical Antipsychotic Drugs Sales Market Share by Application (2015-2020)

12 Company Profiles and Key Figures in Atypical Antipsychotic Drugs Business
12.1 Novartis AG
12.1.1 Novartis AG Atypical Antipsychotic Drugs Corporation Information
12.1.2 Novartis AG Atypical Antipsychotic Drugs Business Overview and Total Revenue
12.1.3 Novartis AG Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Novartis AG Atypical Antipsychotic Drugs Products Offered
12.1.5 Novartis AG Recent Development
12.2 Cardinal Health
12.2.1 Cardinal Health Atypical Antipsychotic Drugs Corporation Information
12.2.2 Cardinal Health Atypical Antipsychotic Drugs Business Overview and Total Revenue
12.2.3 Cardinal Health Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Cardinal Health Atypical Antipsychotic Drugs Products Offered
12.2.5 Cardinal Health Recent Development
12.3 Johnson and Johnson
12.3.1 Johnson and Johnson Atypical Antipsychotic Drugs Corporation Information
12.3.2 Johnson and Johnson Atypical Antipsychotic Drugs Business Overview and Total Revenue
12.3.3 Johnson and Johnson Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Johnson and Johnson Atypical Antipsychotic Drugs Products Offered
12.3.5 Johnson and Johnson Recent Development
12.4 Allergan
12.4.1 Allergan Atypical Antipsychotic Drugs Corporation Information
12.4.2 Allergan Atypical Antipsychotic Drugs Business Overview and Total Revenue
12.4.3 Allergan Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Allergan Atypical Antipsychotic Drugs Products Offered
12.4.5 Allergan Recent Development
12.5 Sanis Health
12.5.1 Sanis Health Atypical Antipsychotic Drugs Corporation Information
12.5.2 Sanis Health Atypical Antipsychotic Drugs Business Overview and Total Revenue
12.5.3 Sanis Health Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Sanis Health Atypical Antipsychotic Drugs Products Offered
12.5.5 Sanis Health Recent Development
12.6 Pfizer
12.6.1 Pfizer Atypical Antipsychotic Drugs Corporation Information
12.6.2 Pfizer Atypical Antipsychotic Drugs Business Overview and Total Revenue
12.6.3 Pfizer Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Pfizer Atypical Antipsychotic Drugs Products Offered
12.6.5 Pfizer Recent Development
12.7 GlaxoSmithKline
12.7.1 GlaxoSmithKline Atypical Antipsychotic Drugs Corporation Information
12.7.2 GlaxoSmithKline Atypical Antipsychotic Drugs Business Overview and Total Revenue
12.7.3 GlaxoSmithKline Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2015-2020)
12.7.4 GlaxoSmithKline Atypical Antipsychotic Drugs Products Offered
12.7.5 GlaxoSmithKline Recent Development
12.8 Bristol-Myers Squibb Company
12.8.1 Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Corporation Information
12.8.2 Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Business Overview and Total Revenue
12.8.3 Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Products Offered
12.8.5 Bristol-Myers Squibb Company Recent Development
12.9 Sun Pharmaceutical Industries
12.9.1 Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Corporation Information
12.9.2 Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Business Overview and Total Revenue
12.9.3 Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Products Offered
12.9.5 Sun Pharmaceutical Industries Recent Development
12.10 Eil Lilly and Company
12.10.1 Eil Lilly and Company Atypical Antipsychotic Drugs Corporation Information
12.10.2 Eil Lilly and Company Atypical Antipsychotic Drugs Business Overview and Total Revenue
12.10.3 Eil Lilly and Company Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Eil Lilly and Company Atypical Antipsychotic Drugs Products Offered
12.10.5 Eil Lilly and Company Recent Development
12.11 AstraZeneca
12.11.1 AstraZeneca Atypical Antipsychotic Drugs Corporation Information
12.11.2 AstraZeneca Atypical Antipsychotic Drugs Business Overview and Total Revenue
12.11.3 AstraZeneca Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2015-2020)
12.11.4 AstraZeneca Atypical Antipsychotic Drugs Products Offered
12.11.5 AstraZeneca Recent Development
12.12 Sumitomo Dainippon Pharma
12.12.1 Sumitomo Dainippon Pharma Atypical Antipsychotic Drugs Corporation Information
12.12.2 Sumitomo Dainippon Pharma Atypical Antipsychotic Drugs Business Overview and Total Revenue
12.12.3 Sumitomo Dainippon Pharma Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2015-2020)
12.12.4 Sumitomo Dainippon Pharma Atypical Antipsychotic Drugs Products Offered
12.12.5 Sumitomo Dainippon Pharma Recent Development
12.13 Qilu Pharmaceutical
12.13.1 Qilu Pharmaceutical Atypical Antipsychotic Drugs Corporation Information
12.13.2 Qilu Pharmaceutical Atypical Antipsychotic Drugs Business Overview and Total Revenue
12.13.3 Qilu Pharmaceutical Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2015-2020)
12.13.4 Qilu Pharmaceutical Atypical Antipsychotic Drugs Products Offered
12.13.5 Qilu Pharmaceutical Recent Development

13 Atypical Antipsychotic Drugs Manufacturing Cost Analysis
13.1 Atypical Antipsychotic Drugs Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Atypical Antipsychotic Drugs
13.4 Atypical Antipsychotic Drugs Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Atypical Antipsychotic Drugs Distributors List
14.3 Atypical Antipsychotic Drugs Customers

15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis

16 Research Findings and Conclusion

17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

List of Tables
Table 1. Global Atypical Antipsychotic Drugs Sales (K Units) Growth Rate by Type (2020-2026)
Table 2. Global Atypical Antipsychotic Drugs Sales (K Units) Comparison by Application (2020-2026)
Table 3. COVID-19 Impact Global Market: (Four Atypical Antipsychotic Drugs Market Size Forecast Scenarios)
Table 4. Opportunities and Trends for Atypical Antipsychotic Drugs Players in the COVID-19 Landscape
Table 5. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 6. Key Regions/Countries Measures against Covid-19 Impact
Table 7. Proposal for Atypical Antipsychotic Drugs Players to Combat Covid-19 Impact
Table 8. Global Market Atypical Antipsychotic Drugs Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 9. Global Atypical Antipsychotic Drugs Sales (K Units) by Region (2015-2020)
Table 10. Global Atypical Antipsychotic Drugs Sales Market Share by Region (2015-2020)
Table 11. Global Atypical Antipsychotic Drugs Revenue (US$ Million) Market Share by Region (2015-2020))
Table 12. Global Atypical Antipsychotic Drugs Revenue Share by Region (2015-2020)
Table 13. Global Atypical Antipsychotic Drugs Sales (K Units) Forecast by Region (2021-2026)
Table 14. Global Atypical Antipsychotic Drugs Sales Market Share Forecast by Region (2021-2026)
Table 15. Global Atypical Antipsychotic Drugs Revenue (US$ Million) Forecast by Region (2021-2026)
Table 16. Global Atypical Antipsychotic Drugs Revenue Share Forecast by Region (2021-2026)
Table 17. Global Atypical Antipsychotic Drugs (K Units) of Key Companies (2015-2020)
Table 18. Global Atypical Antipsychotic Drugs Sales Share by Company (2015-2020)
Table 19. Global Atypical Antipsychotic Drugs Revenue (US$ Million) by Company (2015-2020)
Table 20. Global Atypical Antipsychotic Drugs Revenue Share by Company (2015-2020)
Table 21. Global Atypical Antipsychotic Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Atypical Antipsychotic Drugs as of 2019)
Table 22. Global Atypical Antipsychotic Drugs Average Price (USD/Unit) of Key Company (2015-2020)
Table 23. Manufacturers Atypical Antipsychotic Drugs Manufacturing Sites and Area Served
Table 24. Manufacturers Atypical Antipsychotic Drugs Product Type
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Main Points Interviewed from Key Atypical Antipsychotic Drugs Players
Table 27. Global Atypical Antipsychotic Drugs Sales (K Units) by Type (2015-2020)
Table 28. Global Atypical Antipsychotic Drugs Sales Share by Type (2015-2020)
Table 29. Global Atypical Antipsychotic Drugs Revenue (US$ Million) Market Share by Type (2015-2020)
Table 30. Global Atypical Antipsychotic Drugs Price (K Units) by Type (2015-2020)
Table 31. Global Atypical Antipsychotic Drugs Sales Share by Type (2021-2026)
Table 32. Global Atypical Antipsychotic Drugs Revenue (US$ Million) Market Share by Type (2021-2026)
Table 33. Global Atypical Antipsychotic Drugs Revenue Share by Type (2021-2026)
Table 34. Global Atypical Antipsychotic Drugs Price (K Units) by Type (2021-2026)
Table 35. Global Atypical Antipsychotic Drugs Sales (K Units) by Application (2015-2020)
Table 36. Global Atypical Antipsychotic Drugs Sales Share by Application (2015-2020)
Table 37. Global Atypical Antipsychotic Drugs Revenue (US$ Million) Market Share by Application (2015-2020)
Table 38. Global Atypical Antipsychotic Drugs Price (K Units) by Application (2015-2020)
Table 39. Global Atypical Antipsychotic Drugs Sales (K Units) by Application (2021-2026)
Table 40. Global Atypical Antipsychotic Drugs Sales Share by Application (2021-2026)
Table 41. Global Atypical Antipsychotic Drugs Revenue (US$ Million) Market Share by Application (2021-2026)
Table 42. Global Atypical Antipsychotic Drugs Revenue Share by Application (2021-2026)
Table 43. Global Atypical Antipsychotic Drugs Price (K Units) by Application (2021-2026)
Table 44. United States Atypical Antipsychotic Drugs Sales (K Units) by Company (2015-2020)
Table 45. United States Atypical Antipsychotic Drugs Sales Market Share by Company (2015-2020)
Table 46. United States Atypical Antipsychotic Drugs Sales (K Units) by Type (2015-2020)
Table 47. United States Atypical Antipsychotic Drugs Sales Market Share by Type (2015-2020)
Table 48. United States Atypical Antipsychotic Drugs Sales (K Units) by Application (2015-2020)
Table 49. United States Atypical Antipsychotic Drugs Sales Market Share by Application (2015-2020)
Table 50. Europe Atypical Antipsychotic Drugs Sales (K Units) by Company (2015-2020)
Table 51. Europe Atypical Antipsychotic Drugs Sales Market Share by Company (2015-2020)
Table 52. Europe Atypical Antipsychotic Drugs Sales (K Units) by Type (2015-2020)
Table 53. Europe Atypical Antipsychotic Drugs Sales Market Share by Type (2015-2020)
Table 54. Europe Atypical Antipsychotic Drugs Sales (K Units) by Application (2015-2020)
Table 55. Europe Atypical Antipsychotic Drugs Sales Market Share by Type (2015-2020)
Table 56. China Atypical Antipsychotic Drugs Sales (K Units) by Company (2015-2020)
Table 57. China Atypical Antipsychotic Drugs Sales Market Share by Company (2015-2020)
Table 58. China Atypical Antipsychotic Drugs Sales (K Units) by Type (2015-2020)
Table 59. China Atypical Antipsychotic Drugs Sales Market Share by Type (2015-2020)
Table 60. China Atypical Antipsychotic Drugs Sales (K Units) by Application (2015-2020)
Table 61. China Atypical Antipsychotic Drugs Sales Market Share by Application (2015-2020)
Table 62. Japan Atypical Antipsychotic Drugs Sales (K Units) by Company (2015-2020)
Table 63. Japan Atypical Antipsychotic Drugs Sales Market Share by Company (2015-2020)
Table 64. Japan Atypical Antipsychotic Drugs Sales (K Units) by Type (2015-2020)
Table 65. Japan Atypical Antipsychotic Drugs Sales Market Share by Type (2015-2020)
Table 66. Japan Atypical Antipsychotic Drugs Sales (K Units) by Application (2015-2020)
Table 67. Japan Atypical Antipsychotic Drugs Sales Market Share by Application (2015-2020)
Table 68. Southeast Asia Atypical Antipsychotic Drugs Sales (K Units) by Company (2015-2020)
Table 69. Southeast Asia Atypical Antipsychotic Drugs Sales Market Share by Company (2015-2020)
Table 70. Southeast Asia Atypical Antipsychotic Drugs Sales (K Units) by Type (2015-2020)
Table 71. Southeast Asia Atypical Antipsychotic Drugs Sales Market Share by Type (2015-2020)
Table 72. Southeast Asia Atypical Antipsychotic Drugs Sales (K Units) by Type (2015-2020)
Table 73. Southeast Asia Atypical Antipsychotic Drugs Sales Market Share by Application (2015-2020)
Table 74. India Atypical Antipsychotic Drugs Sales (K Units) by Company (2015-2020)
Table 75. India Atypical Antipsychotic Drugs Sales Market Share by Company (2015-2020)
Table 76. India Atypical Antipsychotic Drugs Sales (K Units) by Type (2015-2020)
Table 77. India Atypical Antipsychotic Drugs Sales Market Share by Type (2015-2020)
Table 78. India Atypical Antipsychotic Drugs Sales (K Units) by Application (2015-2020)
Table 79. India Atypical Antipsychotic Drugs Sales Market Share by Application (2015-2020)
Table 80. Novartis AG Corporation Information
Table 81. Novartis AG Description and Business Overview
Table 82. Novartis AG Atypical Antipsychotic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 83. Novartis AG Atypical Antipsychotic Drugs Product
Table 84. Novartis AG Recent Development
Table 85. Cardinal Health Corporation Information
Table 86. Cardinal Health Description and Business Overview
Table 87. Cardinal Health Atypical Antipsychotic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 88. Cardinal Health Atypical Antipsychotic Drugs Product
Table 89. Cardinal Health Recent Development
Table 90. Johnson and Johnson Corporation Information
Table 91. Johnson and Johnson Description and Business Overview
Table 92. Johnson and Johnson Atypical Antipsychotic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 93. Johnson and Johnson Atypical Antipsychotic Drugs Product
Table 94. Johnson and Johnson Recent Development
Table 95. Allergan Corporation Information
Table 96. Allergan Description and Business Overview
Table 97. Allergan Atypical Antipsychotic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 98. Allergan Atypical Antipsychotic Drugs Product
Table 99. Allergan Recent Development
Table 100. Sanis Health Corporation Information
Table 101. Sanis Health Description and Business Overview
Table 102. Sanis Health Atypical Antipsychotic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 103. Sanis Health Atypical Antipsychotic Drugs Product
Table 104. Sanis Health Recent Development
Table 105. Pfizer Corporation Information
Table 106. Pfizer Description and Business Overview
Table 107. Pfizer Atypical Antipsychotic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 108. Pfizer Atypical Antipsychotic Drugs Product
Table 109. Pfizer Recent Development
Table 110. GlaxoSmithKline Corporation Information
Table 111. GlaxoSmithKline Description and Business Overview
Table 112. GlaxoSmithKline Atypical Antipsychotic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 113. GlaxoSmithKline Atypical Antipsychotic Drugs Product
Table 114. GlaxoSmithKline Recent Development
Table 115. Bristol-Myers Squibb Company Corporation Information
Table 116. Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 117. Bristol-Myers Squibb Company Description and Business Overview
Table 118. Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Product
Table 119. Bristol-Myers Squibb Company Recent Development
Table 120. Sun Pharmaceutical Industries Corporation Information
Table 121. Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 122. Sun Pharmaceutical Industries Description and Business Overview
Table 123. Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Product
Table 124. Sun Pharmaceutical Industries Recent Development
Table 125. Eil Lilly and Company Corporation Information
Table 126. Eil Lilly and Company Description and Business Overview
Table 127. Eil Lilly and Company Atypical Antipsychotic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 128. Eil Lilly and Company Atypical Antipsychotic Drugs Product
Table 129. Eil Lilly and Company Recent Development
Table 130. AstraZeneca Corporation Information
Table 131. AstraZeneca Description and Business Overview
Table 132. AstraZeneca Atypical Antipsychotic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 133. AstraZeneca Atypical Antipsychotic Drugs Product
Table 134. AstraZeneca Recent Development
Table 135. Sumitomo Dainippon Pharma Corporation Information
Table 136. Sumitomo Dainippon Pharma Description and Business Overview
Table 137. Sumitomo Dainippon Pharma Atypical Antipsychotic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 138. Sumitomo Dainippon Pharma Atypical Antipsychotic Drugs Product
Table 139. Sumitomo Dainippon Pharma Recent Development
Table . Qilu Pharmaceutical Corporation Information
Table . Qilu Pharmaceutical Description and Business Overview
Table . Qilu Pharmaceutical Atypical Antipsychotic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table . Qilu Pharmaceutical Atypical Antipsychotic Drugs Product
Table . Qilu Pharmaceutical Recent Development
Table 145. Production Base and Market Concentration Rate of Raw Material
Table 146. Key Suppliers of Raw Materials
Table 147. Atypical Antipsychotic Drugs Distributors List
Table 148. Atypical Antipsychotic Drugs Customers List
Table 149. Market Key Trends
Table 150. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 151. Key Challenges
Table 152. Research Programs/Design for This Report
Table 153. Key Data Information from Secondary Sources
Table 154. Key Data Information from Primary Sources
List of Figures
Figure 1. Atypical Antipsychotic Drugs Product Picture
Figure 2. Global Atypical Antipsychotic Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Atypical Antipsychotic Drugs Market Share by Application in 2020 & 2026
Figure 6. Bipolar I Disorder Examples
Figure 7. Schizophrenia Examples
Figure 8. Schizoaffective Disorder Examples
Figure 9. Major Depressive Disorder (MDD) Examples
Figure 10. Global Atypical Antipsychotic Drugs Sales (K Units) Growth Rate (2015-2026)
Figure 11. Global Atypical Antipsychotic Drugs Revenue (US$ Million) Growth Rate (2015-2026)
Figure 12. Global Atypical Antipsychotic Drugs Price Trends Growth Rate (2015-2026) (USD/Unit)
Figure 13. Global Atypical Antipsychotic Drugs Revenue Market Share by Region: 2015 VS 2020
Figure 14. Global Atypical Antipsychotic Drugs Revenue Market Share by Region: 2021 VS 2026
Figure 15. United States Atypical Antipsychotic Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 16. United States Atypical Antipsychotic Drugs Sales (K Units) Growth Rate (2015-2026)
Figure 17. Europe Atypical Antipsychotic Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 18. Europe Atypical Antipsychotic Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 19. China Atypical Antipsychotic Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 20. China Atypical Antipsychotic Drugs Sales (Million USD) and Growth Rate (2015-2026)
Figure 21. Japan Atypical Antipsychotic Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 22. Japan Atypical Antipsychotic Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Atypical Antipsychotic Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 24. Southeast Asia Atypical Antipsychotic Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 25. India Atypical Antipsychotic Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 26. India Atypical Antipsychotic Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 27. Global 5 Largest Atypical Antipsychotic Drugs Players Market Share by Revenue in Atypical Antipsychotic Drugs 2015 & 2019
Figure 28. Atypical Antipsychotic Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 29. Global Atypical Antipsychotic Drugs Revenue Share by Type (2015-2020)
Figure 30. Global Atypical Antipsychotic Drugs Revenue Growth Rate by Type in 2015 & 2019
Figure 31. Global Atypical Antipsychotic Drugs Revenue Share by Application (2015-2020)
Figure 32. Global Atypical Antipsychotic Drugs Revenue Growth Rate by Application in 2015 & 2019
Figure 33. United States Atypical Antipsychotic Drugs Sales Market Share by Type in 2019
Figure 34. United States Atypical Antipsychotic Drugs Sales Market Share by Type in 2019
Figure 35. Europe Atypical Antipsychotic Drugs Sales Market Share by Company in 2019
Figure 36. Europe Atypical Antipsychotic Drugs Sales Market Share by Type in 2019
Figure 37. Europe Atypical Antipsychotic Drugs Sales Market Share by Application in 2019
Figure 38. China Atypical Antipsychotic Drugs Sales Market Share by Company in 2019
Figure 39. China Atypical Antipsychotic Drugs Sales Market Share by Type in 2019
Figure 40. China Atypical Antipsychotic Drugs Sales Market Share by Application in 2019
Figure 41. Japan Atypical Antipsychotic Drugs Sales Market Share by Company in 2019
Figure 42. Japan Atypical Antipsychotic Drugs Sales Market Share by Type in 2019
Figure 43. Japan Atypical Antipsychotic Drugs Sales Market Share by Application in 2019
Figure 44. Southeast Asia Atypical Antipsychotic Drugs Sales Market Share by Company in 2019
Figure 45. Southeast Asia Atypical Antipsychotic Drugs Sales Market Share by Type in 2019
Figure 46. Southeast Asia Atypical Antipsychotic Drugs Sales Market Share by Application in 2019
Figure 47. India Atypical Antipsychotic Drugs Sales Market Share by Company in 2019
Figure 48. India Atypical Antipsychotic Drugs Sales Market Share by Type in 2019
Figure 49. India Atypical Antipsychotic Drugs Sales Market Share by Application in 2019
Figure 50. Novartis AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Cardinal Health Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Johnson and Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Allergan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Sanis Health Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. GlaxoSmithKline Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Bristol-Myers Squibb Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Sun Pharmaceutical Industries Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Eil Lilly and Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Sumitomo Dainippon Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Qilu Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Key Raw Materials Price Trend
Figure 64. Manufacturing Cost Structure of Atypical Antipsychotic Drugs
Figure 65. Manufacturing Process Analysis of Atypical Antipsychotic Drugs
Figure 66. Atypical Antipsychotic Drugs Industrial Chain Analysis
Figure 67. Channels of Distribution
Figure 68. Distributors Profiles
Figure 69. Porter's Five Forces Analysis
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed